Inicio>>Signaling Pathways>> Others>>Apraclonidine (hydrochloride)

Apraclonidine (hydrochloride) (Synonyms: AL0 2145, ALO 2145)

Catalog No.GC42830

La apraclonidina (clorhidrato) (ALO 2145), una actividad agonista selectiva de los receptores α2 y α1 débil, reduce eficazmente la presión intraocular (PIO) en los ojos humanos.

Products are for research use only. Not for human use. We do not sell to patients.

Apraclonidine (hydrochloride) Chemical Structure

Cas No.: 73218-79-8

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
69,00 $
Disponible
5mg
63,00 $
Disponible
10mg
105,00 $
Disponible
25mg
189,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Apraclonidine is an α2-adrenergic receptor (α2-AR) agonist and structural analog of clonidine . It binds to α2-ARs in calf cortex, rat kidney, and rat spleen with IC50 values of 0.9, 4.3, and 4.2 nM, respectively. Apraclonidine also binds to α2-ARs in rat cerebral cortex, pig submandibular gland and lung tissue, and in dog kidney membrane (Kds = 0.87, 5.28, 1.30, and 5.25 nM, respectively). It inhibits noradrenaline-stimulated contraction in guinea pig ileum and rabbit vas deferens (EC50s = 7.59 and 6.76 nM, respectively). Opthalmic formulations containing apraclonidine have been used to treat elevated intraocular pressure.

Reseñas

Review for Apraclonidine (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Apraclonidine (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.